132 related articles for article (PubMed ID: 32079692)
21. Hyper-active non-homologous end joining selects for synthetic lethality resistant and pathological Fanconi anemia hematopoietic stem and progenitor cells.
Du W; Amarachintha S; Wilson AF; Pang Q
Sci Rep; 2016 Feb; 6():22167. PubMed ID: 26916217
[TBL] [Abstract][Full Text] [Related]
22. Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways.
Ghosh R; Roy S; Kamyab J; Danzter F; Franco S
DNA Repair (Amst); 2016 Sep; 45():56-62. PubMed ID: 27373144
[TBL] [Abstract][Full Text] [Related]
23. Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma.
Hu Y; Lin J; Fang H; Fang J; Li C; Chen W; Liu S; Ondrejka S; Gong Z; Reu F; Maciejewski J; Yi Q; Zhao JJ
Leukemia; 2018 Oct; 32(10):2250-2262. PubMed ID: 29632340
[TBL] [Abstract][Full Text] [Related]
24. The non-homologous end-joining activity is required for Fanconi anemia fetal HSC maintenance.
Nie Y; Li Y; Li X; Wilson AF; Pang Q
Stem Cell Res Ther; 2019 Mar; 10(1):114. PubMed ID: 30925933
[TBL] [Abstract][Full Text] [Related]
25. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
Xiong T; Wei H; Chen X; Xiao H
Int J Oncol; 2015 Jan; 46(1):223-32. PubMed ID: 25351371
[TBL] [Abstract][Full Text] [Related]
26. Repair of G1 induced DNA double-strand breaks in S-G2/M by alternative NHEJ.
Yu W; Lescale C; Babin L; Bedora-Faure M; Lenden-Hasse H; Baron L; Demangel C; Yelamos J; Brunet E; Deriano L
Nat Commun; 2020 Oct; 11(1):5239. PubMed ID: 33067475
[TBL] [Abstract][Full Text] [Related]
27. Parp1-XRCC1 and the repair of DNA double strand breaks in mouse round spermatids.
Ahmed EA; de Boer P; Philippens ME; Kal HB; de Rooij DG
Mutat Res; 2010 Jan; 683(1-2):84-90. PubMed ID: 19887075
[TBL] [Abstract][Full Text] [Related]
28. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.
Yang S; Wang XQ
BMC Cancer; 2017 May; 17(1):344. PubMed ID: 28526069
[TBL] [Abstract][Full Text] [Related]
29. Environmental Stress Induces Trinucleotide Repeat Mutagenesis in Human Cells by Alt-Nonhomologous End Joining Repair.
Chatterjee N; Lin Y; Yotnda P; Wilson JH
J Mol Biol; 2016 Jul; 428(15):2978-80. PubMed ID: 27318194
[TBL] [Abstract][Full Text] [Related]
30. BRCA2 antagonizes classical and alternative nonhomologous end-joining to prevent gross genomic instability.
Han J; Ruan C; Huen MSY; Wang J; Xie A; Fu C; Liu T; Huang J
Nat Commun; 2017 Nov; 8(1):1470. PubMed ID: 29133916
[TBL] [Abstract][Full Text] [Related]
31. [Double strand break repair, one mechanism can hide another: alternative non-homologous end joining].
Rass E; Grabarz A; Bertrand P; Lopez BS
Cancer Radiother; 2012 Feb; 16(1):1-10. PubMed ID: 21737335
[TBL] [Abstract][Full Text] [Related]
32. Impaired DNA double-strand break repair contributes to the age-associated rise of genomic instability in humans.
Li Z; Zhang W; Chen Y; Guo W; Zhang J; Tang H; Xu Z; Zhang H; Tao Y; Wang F; Jiang Y; Sun FL; Mao Z
Cell Death Differ; 2016 Nov; 23(11):1765-1777. PubMed ID: 27391797
[TBL] [Abstract][Full Text] [Related]
33. Sensitizing thermochemotherapy with a PARP1-inhibitor.
Oei AL; Vriend LE; van Leeuwen CM; Rodermond HM; Ten Cate R; Westermann AM; Stalpers LJ; Crezee J; Kanaar R; Kok HP; Krawczyk PM; Franken NA
Oncotarget; 2017 Mar; 8(10):16303-16312. PubMed ID: 27557507
[TBL] [Abstract][Full Text] [Related]
34. H3K36 dimethylation by MMSET promotes classical non-homologous end-joining at unprotected telomeres.
de Krijger I; van der Torre J; Peuscher MH; Eder M; Jacobs JJL
Oncogene; 2020 Jun; 39(25):4814-4827. PubMed ID: 32472076
[TBL] [Abstract][Full Text] [Related]
35. Kinesin Kif2C in regulation of DNA double strand break dynamics and repair.
Zhu S; Paydar M; Wang F; Li Y; Wang L; Barrette B; Bessho T; Kwok BH; Peng A
Elife; 2020 Jan; 9():. PubMed ID: 31951198
[TBL] [Abstract][Full Text] [Related]
36. Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress.
Chroma K; Mistrik M; Moudry P; Gursky J; Liptay M; Strauss R; Skrott Z; Vrtel R; Bartkova J; Kramara J; Bartek J
Oncogene; 2017 Apr; 36(17):2405-2422. PubMed ID: 27841863
[TBL] [Abstract][Full Text] [Related]
37. Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.
Park Y; Chui MH; Suryo Rahmanto Y; Yu ZC; Shamanna RA; Bellani MA; Gaillard S; Ayhan A; Viswanathan A; Seidman MM; Franco S; Leung AKL; Bohr VA; Shih IM; Wang TL
Clin Cancer Res; 2019 Sep; 25(18):5584-5594. PubMed ID: 31196855
[TBL] [Abstract][Full Text] [Related]
38. Role for Artemis nuclease in the repair of radiation-induced DNA double strand breaks by alternative end joining.
Moscariello M; Wieloch R; Kurosawa A; Li F; Adachi N; Mladenov E; Iliakis G
DNA Repair (Amst); 2015 Jul; 31():29-40. PubMed ID: 25973742
[TBL] [Abstract][Full Text] [Related]
39. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
40. BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy.
Oing C; Tennstedt P; Simon R; Volquardsen J; Borgmann K; Bokemeyer C; Petersen C; Dikomey E; Rothkamm K; Mansour WY
Cancer Lett; 2018 Jun; 423():60-70. PubMed ID: 29526801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
